## <sup>1</sup>Brilliant Futures™ Myopia Management Program Agreement

Welcome to the Brilliant Futures Myopia Management Program
Offered by Dr. Bei Zhang Optometrist, INC

#### 1. Introduction:

\*MiSight 1 day® contact lens is the only FDA approved² soft contact lens indicated to slow the progression of myopia (nearsightedness) in children, aged 8-12 at the initiation of treatment. Slowing of myopia progression is expected but not guaranteed. We are excited to journey together with your family in this program now and into the future. We are committed to being available on this journey and we ask for your commitment to the visit schedule and lens wear expectations.

### 2. Wear Time

The children in the clinical trial were asked to wear their lenses  $\geq$  10 hours per day and  $\geq$  6 days per week. Most enjoyed wearing their lenses for 11 to 14 hours per day.<sup>1,2</sup>

### 3. Lens Wear - Application and Removal

To optimize a successful wearing experience, please review and follow the application and removal instructions provided separately.

If at any time during the program your child experiences eye pain, discomfort, and/or redness, your child should remove the lenses immediately and you should contact our practice to speak with your doctor (or if the office is closed, contact our after-hours phone number at 925-481-5641 (text message), or email drzhang@drbeizhangoptometristinc.com drkaing@drbeizhangoptometristinc.com drnguyen@drbeizhangoptometristinc.com

## 4. Follow-Up Visits

This is an expected visit schedule to monitor your child's progression. Your doctor will determine the most appropriate interval and number of visits, all included in the program.

Year 1	Year 2 and onwards
Comprehensive Eye Exam	Comprehensive Eye Exam
Myopia Consultation	-
Contact Lens Training	
1 week	-
6 months	6 months

<sup>&</sup>lt;sup>1</sup> The Brilliant Futures™ trademark and MiSight© 1 day copyright is owned by CooperVision, Inc.

 $<sup>^2</sup>$  Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

### 5. Costs

Program fee (each year): \$1,800 before manufacture mail in rebate Doctor service fee \$440, MiSight annual supply \$1,360.

What's included in your Brilliant Futures Myopia Management Program fee:

- MiSight consultation
- 20 pairs of trial lenses
- CL insertion and removal training
- An annual supply of MiSight
- Free shipping of contact lenses, exchanges and returns for any power changes whether boxes are opened or unopened
- 6-month refraction

Diagnosis and treatment of any eye infection, corneal abrasions, or other eye conditions other than myopia are not part of the Brilliant Futures Myopia Management Program and are therefore subject to additional expenses and, if applicable, your medical insurance co-pays and deductibles.

# 6. Acknowledgement:

I have read all the above information and understand the commitment asked of my child and I to maximize my child's success. I agree to contact my doctor as outlined in section 3 if anything abnormal was to arise.

I hereby authorize Dr Bei Zhang to initiate the Brilliant Futures Myopia Management Program with MiSight 1 day contact lenses for the child identified below.

Child's name:
Parent or legal guardian signature:
Doctor signature:
Brilliant Futures Myopia Management Program
Certified Eye Care Professional
Bei Zhang O.D.
Karena Kaing O.D.
Aline Nguyen O.D.
Dr Bei Zhang Optometrist, INC
Date:/

<sup>&</sup>lt;sup>1</sup>Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-567.

<sup>&</sup>lt;sup>2</sup>Chamberlain P et al. Further comparison of myopia progression in new and established myopia control treatment (MiSight® 1 day) groups. BCLA paper presentation 2019.